IBC-Ab002 Shows Early Promise in Phase 1b Alzheimer’s Trial

A first-in-human Phase 1b investigation published in Nature Medicine found that the investigational anti-PD-L1 monoclonal antibody IBC-Ab002 was generally well tolerated in individuals with early Alzheimer’s disease. Rather than directly targeting amyloid or tau, this therapy is designed to transiently stimulate peripheral immune responses to counter neuroinflammation, supporting continued clinical development of this novel approach.

Study Design

The multicentre Phase 1b IBC-01-01 trial (NCT05551741) was a randomized, double-blind, placebo-controlled, dose-escalation study conducted across 11 centres in the United Kingdom, Israel, and the Netherlands. Forty participants aged 50–80 years with biomarker-confirmed early symptomatic Alzheimer’s disease received placebo or intravenous IBC-Ab002 (1, 3, 6, 15, or 30 mg/kg) every 12 weeks for four doses. Participants met biomarker criteria consistent with amyloid-positive and tau-positive (A+T+) Alzheimer’s disease. The primary objective was safety and tolerability, while secondary and exploratory endpoints evaluated pharmacokinetics, immunogenicity, PD-L1 receptor occupancy, immune activation, cerebrospinal fluid (CSF) biomarkers, and cognitive outcomes.

Safety, Tolerability, and Pharmacokinetic Findings

IBC-Ab002 showed a favourable safety profile throughout the study. No treatment-related serious adverse events or amyloid-related imaging abnormalities (ARIA) were reported. The most common adverse events, including fatigue, headache, and infusion-related reactions, were mild to moderate. Immune-related adverse events occurred in approximately one-third of treated participants and primarily consisted of asymptomatic thyroid dysfunction, with most events being mild to moderate in severity. One participant experienced reversible grade 3 hepatic transaminase elevation that resolved spontaneously after treatment discontinuation. Pharmacokinetic analyses confirmed the intended short half-life of approximately four days, absence of drug accumulation, and dose-dependent PD-L1 receptor occupancy. Although treatment-emergent anti-drug antibodies developed in many participants receiving IBC-Ab002, they did not meaningfully affect drug exposure or pharmacokinetic parameters.

Pharmacodynamic Activity, Biomarker Findings, and Clinical Outcomes

Transient peripheral immune activation confirmed successful target engagement. At the highest evaluated dose of 30 mg/kg, exploratory CSF analyses demonstrated directional reductions in neurogranin, total tau, and phosphorylated tau181, whereas Aβ1-42, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and soluble TREM2 remained largely unchanged. These exploratory analyses were based on the subset of participants who consented to the optional week 48 lumbar puncture, and none of the biomarker changes reached statistical significance because of the limited sample size. Consequently, these findings should be interpreted as hypothesis-generating rather than evidence of clinical efficacy. MMSE and Cognitive-Functional Composite scores remained generally stable during follow-up, although the study was not powered to detect clinical benefit.

Clinical Significance

Unlike currently available anti-amyloid monoclonal antibodies, IBC-Ab002 aims to restore age-related peripheral immune function instead of directly clearing amyloid. The encouraging safety profile and evidence of biological activity support advancement into larger efficacy trials while highlighting a potentially complementary therapeutic strategy for Alzheimer’s disease.

Researcher Perspective

The investigators concluded that transient PD-L1 blockade may help reactivate protective immune mechanisms that decline with ageing, potentially reducing chronic neuroinflammation while avoiding prolonged immune checkpoint inhibition.

Path Forward

These first-in-human findings establish proof of safety and biological mechanism but do not demonstrate clinical efficacy. Larger Phase 2 studies are needed to determine whether the observed exploratory biomarker trends translate into meaningful slowing of cognitive decline and disease progression. By targeting immune modulation rather than directly removing amyloid, IBC-Ab002 represents a novel therapeutic strategy for Alzheimer’s disease. If future clinical trials confirm efficacy, this approach could expand the range of disease-modifying treatment options available for patients with early Alzheimer’s disease.

References

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial | Nature Medicine